SDC2 and cancer: They identified as potential therapeutic target the ligand-receptor interaction between midkine (MDK, expressed in cancer-associated fibroblasts), a growth factor that acts on cancer progression and NCL/SDC2/SDC4 (expressed in cancer cells), highlighting the co-receptor role of syndecans for pro-tumorigenic signaling.